ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.

doi:10.1038/s41588-019-0554-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.

Nature genetics - 1 Feb 2020

Xu Guotai, Chhangawala Sagar, Cocco Emiliano, Razavi Pedram, Cai Yanyan, Otto Jordan E, Ferrando Lorenzo, Selenica Pier, Ladewig Erik, Chan Carmen, Da Cruz Paula Arnaud, Witkin Matthew, Cheng Yuanming, Park Jane, Serna-Tamayo Cristian, Zhao HuiYong, Wu Fan, Sallaku Mirna, Qu Xuan, Zhao Alison, Collings Clayton K, D'Avino Andrew R, Jhaveri Komal, Koche Richard, Levine Ross L, Reis-Filho Jorge S, Kadoch Cigall, Scaltriti Maurizio, Leslie Christina S, Baselga José, Toska Eneda

Abstract excerpt

Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are the most common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER+) breast cancer. We identify that ARID1A inactivating mutations are present at a high frequency in advanced endocrine-resistant ER+ breast cancer. An epigenome CRISPR-CAS9 knockout (KO) screen identifies ARID1A as the top candidate whose loss...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Chromatin

Share to Drug Resistance, Neoplasm

Share to GATA3 Transcription Factor

Share to Hepatocyte Nuclear Factor 3-alpha

Share to Receptors, Estrogen

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 31932695
DOI: 10.1038/s41588-019-0554-0
PMCID: PMC7341683

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.PMID 31932695Read ↗

ARID1A and Its Impact Across the Hallmarks of CancerSemantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

ARID1A orchestrates the activity of FOXA1 and AP-2 transcription factors in lobular breast cancer cellsSemantic proximity Read ↗

ARID1A loss in cancer: Towards a mechanistic understanding.Semantic proximity Read ↗

The emerging roles of ARID1A in tumor suppression.Semantic proximity Read ↗

ARID1A in Gynecologic Precancers and Cancers.Semantic proximity Read ↗

ARID1A mutations in cancer development: mechanism and therapy.Semantic proximity Read ↗

Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cellsSemantic proximity Read ↗

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor TherapySemantic proximity Read ↗

The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?Semantic proximity Read ↗

Acute depletion of the ARID1A subunit of SWI/SNF complexes reveals distinct pathways for activation and repression of transcriptionSemantic proximity Read ↗

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic TargetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.